Pharmaceutical companies establish a Wholesale Acquisition Cost (WAC), which serves as the official list price before insurance negotiations
Novel tri-agonists (targeting GLP-1, GIP, and glucagon) like retatrutide are in early development (37, 44) Adult data show that tirzepatide produces substantially greater BMI reduction than GLP-1 monotherapy (37), suggesting these agents could revolutionize pediatric treatment if found safe and effective in youth
[16] [17] Many patients with type 2 diabetes or obesity also have cardiovascular comorbidities requiring anticoagulation therapy
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Neeland I.J., Linge J., Birkenfeld A.L
The WHO recommends lower cutoffs for Asian populations: obesity at BMI 27.5 (versus 30 standard) and overweight at BMI 23 (versus 25 standard)
Die kardiovaskulren Events wurden um 30%, die Nierenereignisse um 57% gesenkt